X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (231) 231
humans (184) 184
animals (176) 176
glucose (141) 141
diabetes (105) 105
male (98) 98
sodium-glucose transporter 2 - antagonists & inhibitors (93) 93
diabetes mellitus, type 2 - drug therapy (90) 90
dextrose (87) 87
glucose - metabolism (85) 85
type 2 diabetes (76) 76
sodium-glucose transporter 1 - metabolism (69) 69
hypoglycemic agents - therapeutic use (68) 68
sodium (68) 68
rats (65) 65
pharmacology & pharmacy (63) 63
diabetes mellitus (59) 59
glucose metabolism (59) 59
endocrinology & metabolism (58) 58
sodium-glucose transporter 2 - metabolism (58) 58
dapagliflozin (57) 57
insulin (53) 53
hyperglycemia (48) 48
mice (48) 48
physiology (48) 48
double-blind (44) 44
female (44) 44
hypoglycemic agents - pharmacology (42) 42
blood glucose - metabolism (40) 40
glucosides - therapeutic use (39) 39
diabetes mellitus, type 2 - metabolism (38) 38
analysis (37) 37
rodents (37) 37
sodium-glucose transporter 1 (36) 36
internal medicine (35) 35
expression (34) 34
sglt1 (34) 34
sglt2 inhibitor (34) 34
biochemistry & molecular biology (33) 33
monosaccharide transport proteins - metabolism (32) 32
research (32) 32
blood pressure (31) 31
kidney - metabolism (31) 31
transporter (31) 31
canagliflozin (30) 30
glucose transporter (30) 30
hypoglycemic agents - adverse effects (30) 30
medicine & public health (30) 30
sglt2 inhibitors (30) 30
treatment outcome (30) 30
cell biology (29) 29
glycemic control (29) 29
inadequate glycemic control (29) 29
proteins (29) 29
glucosides - pharmacology (28) 28
sodium - metabolism (28) 28
benzhydryl compounds - therapeutic use (27) 27
diabetes mellitus, type 2 - complications (26) 26
membrane glycoproteins - metabolism (26) 26
metabolism (26) 26
sodium-glucose transporter 1 - antagonists & inhibitors (26) 26
type-2 diabetes-mellitus (26) 26
empagliflozin (25) 25
gene expression (25) 25
kidney (25) 25
physiological aspects (25) 25
review (25) 25
safety (25) 25
absorption (24) 24
blood sugar (24) 24
diabetes mellitus, type 2 - blood (24) 24
sodium-glucose transporter 1 - genetics (24) 24
type 2 diabetes mellitus (24) 24
body weight (23) 23
diabetes therapy (23) 23
drug therapy (23) 23
hypoglycemic agents (23) 23
intestine (23) 23
medicine (23) 23
middle aged (23) 23
secretion (23) 23
sglt2 (23) 23
dose-response relationship, drug (22) 22
health aspects (22) 22
intestinal mucosa - metabolism (22) 22
jejunum - metabolism (22) 22
kidney - drug effects (22) 22
multidisciplinary sciences (22) 22
obesity (22) 22
rats, sprague-dawley (22) 22
blood-pressure (21) 21
glucagon-like peptide-1 (21) 21
inhibitors (21) 21
insulin resistance (21) 21
na+/glucose cotransporter (21) 21
article (20) 20
blood glucose - drug effects (20) 20
care and treatment (20) 20
clinical trials (20) 20
heart failure (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC VETERINARY RESEARCH, ISSN 1746-6148, 02/2019, Volume 15
BackgroundA previous six-week (wk) study demonstrated the potential of the sodium-glucose linked transport inhibitor velagliflozin as a novel treatment for... 
LEPTIN | HOMEOSTASIS | Equine metabolic syndrome | Laminitis | BODY-FAT MASS | SODIUM GLUCOSE CO-TRANSPORTER-2 | HYPERINSULINEMIA | RESTRICTION | COMBINATION | Insulin | VETERINARY SCIENCES | Sodium-glucose linked transport inhibitor | WEIGHT | PASTURE-ASSOCIATED LAMINITIS
Journal Article
BMC veterinary research, ISSN 1746-6148, 02/2019, Volume 15, Issue 1, pp. 65 - 10
A previous six-week (wk) study demonstrated the potential of the sodium-glucose linked transport inhibitor velagliflozin as a novel treatment for equine... 
Metabolic diseases | Hypoglycemic agents | Ponies | Drug therapy | Insulin | Health aspects | Testing | Carbohydrates | Hyperinsulinemia | Effectiveness | Hematology | Body fat | Biochemistry | Glucose | Hypoglycemia | Glucose transport | Metabolic syndrome | Studies | Diet | Sodium | Metabolites | Insulin resistance | Diabetes | Safety | Fat body | Sodium-glucose linked transport inhibitor | Equine metabolic syndrome | Laminitis
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2015, Volume 17, Issue 6, pp. 591 - 598
Aim To investigate the efficacy and safety of ertugliflozin, in a phase II dose‐ranging study, in patients with type 2 diabetes mellitus (T2DM) inadequately... 
sodium‐glucose linked co‐transporter (SGLT) | PF‐04971729 | ertugliflozin | HbA1c | type 2 diabetes mellitus (T2DM) | Sodium-glucose linked co-transporter (SGLT) | Ertugliflozin | PF-04971729 | Type 2 diabetes mellitus (T2DM) | sodium-glucose linked co-transporter (SGLT) | GLYCEMIC CONTROL | MONOTHERAPY | DAPAGLIFLOZIN | PLUS SULFONYLUREA | SITAGLIPTIN | RANDOMIZED-TRIAL | MELLITUS | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Genital Diseases, Female - chemically induced | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adult | Female | Blood Pressure - drug effects | Metformin - administration & dosage | Hypoglycemia - chemically induced | Sitagliptin Phosphate - administration & dosage | Double-Blind Method | Genital Diseases, Male - chemically induced | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Drug Therapy, Combination - methods | Aged | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Mycoses - chemically induced | Type 2 diabetes | Complications and side effects | Medical research | Care and treatment | Mycoses | Medicine, Experimental | Hemoglobin | Urinary tract infections | Hypoglycemic agents | Glucose | Dextrose | Blood pressure | Diabetes | Glucose transporter | Sodium | Diabetes mellitus | Body weight | Urinary tract | Safety | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent)
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 07/2018, Volume 17, Issue 1, pp. 99 - 13
Background: Inhibiting both type 1 and 2 sodium-glucose linked cotransporter (SGLT1/2) offers the potential to not only increase glucosuria beyond that seen... 
Myocardial infarction | Sodium-glucose linked cotransporter | Systole | Diastole | MORTALITY | FIBROSIS | SELECTIVE SGLT2 INHIBITOR | PRESSURE-OVERLOAD | CARDIAC & CARDIOVASCULAR SYSTEMS | TRANSPORTER | PROTEIN | DAPAGLIFLOZIN | HEART-FAILURE | LEFT-VENTRICULAR HYPERTROPHY | ENDOCRINOLOGY & METABOLISM | EMPAGLIFLOZIN | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Glucosides - pharmacology | Glucosides - toxicity | Sodium-Glucose Transporter 2 - metabolism | Hypertrophy, Left Ventricular - metabolism | Rats, Inbred F344 | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Ventricular Function, Left - drug effects | Male | Myocardial Infarction - metabolism | Ventricular Dysfunction, Left - chemically induced | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - metabolism | Carbonates - toxicity | Hypertrophy, Left Ventricular - chemically induced | Animals | Myocardium - metabolism | Myocardial Infarction - physiopathology | Benzhydryl Compounds - pharmacology | Sodium-Glucose Transporter 1 - metabolism | Hypertrophy, Left Ventricular - physiopathology | Ventricular Remodeling - drug effects | Disease Models, Animal | Heart | Diastolic pressure | Heart attacks | Glucagon | Myocytes | Glucose | Rodents | Blood pressure | Inhibition | Drug therapy | Heart diseases | Time constant | Glucagon-like peptide 1 | Heart failure | Echocardiography | Kidneys | Catheterization | Secretion | Coronary artery | Organs | Rats | Cardiomyocytes | Glucose transport | Coronary artery disease | Studies | Ostomy | Inhibitors | Sodium | Lungs | Coronary vessels | Infarction | Ventricle | Diabetes | Prolongation | Ejection | Veins & arteries | Sodium–glucose linked cotransporter
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 2812 - 9
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 11/2013, Volume 170, Issue 5, pp. 1041 - 1052
Background and Purpose Intestinal nutrient transporters may mediate the uptake of drugs. The aim of this study was to investigate whether sertraline interacts... 
small intestinal absorption | PAT1 (SLC36A1) | in vivo transporter | transporter‐mediated pharmacokinetics | gaboxadol | sertraline | transporter-mediated pharmacokinetics | RAT | SLC36A1 HPAT1 | ARRIVE GUIDELINES | L-TRYPTOPHAN | AMINO-ACID TRANSPORTER | SEROTONIN REUPTAKE INHIBITORS | PHARMACOKINETICS | GABOXADOL ABSORPTION | PHARMACOLOGY & PHARMACY | DRUG TRANSPORT | CACO-2 CELLS | Intestinal Mucosa - metabolism | Area Under Curve | Proline - metabolism | Humans | Intestinal Absorption - drug effects | Biological Availability | Male | Intestinal Mucosa - drug effects | Dose-Response Relationship, Drug | Tandem Mass Spectrometry | Symporters - antagonists & inhibitors | Isoxazoles - blood | Sodium-Glucose Transporter 1 - metabolism | Caco-2 Cells | Isoxazoles - pharmacokinetics | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Sertraline - pharmacology | Peptide Transporter 1 | Administration, Oral | Xenopus laevis | Chromatography - methods | Rats | Amino Acid Transport Systems, Neutral - metabolism | Amino Acid Transport Systems - antagonists & inhibitors | Amino Acid Transport Systems - metabolism | Rats, Sprague-Dawley | Isoxazoles - administration & dosage | Symporters - metabolism | Animals | Hydrophobic and Hydrophilic Interactions | Serotonin Uptake Inhibitors - pharmacology | Amino Acid Transport Systems, Neutral - antagonists & inhibitors | Glucose metabolism | Enzyme inhibitors | Glucose | Glycine | Sertraline | Dextrose | Research Papers
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk... 
cardiovascular disease | DPP‐4 inhibitor | type 2 diabetes | diabetes complications | hypoglycaemia | dapagliflozin | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article